QuidelOrtho (QDEL) Projected to Post Earnings on Tuesday

QuidelOrtho (NASDAQ:QDEL) is expected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of $0.2023 per share and revenue of $627.83 million for the quarter. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Parties may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 5:00 PM ET.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18. The firm had revenue of $630.90 million for the quarter, compared to analysts’ expectations of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.12 earnings per share. On average, analysts expect QuidelOrtho to post $0.75 EPS for the current fiscal year and $1.45 EPS for the next fiscal year.

QuidelOrtho Price Performance

Shares of QDEL opened at $13.68 on Tuesday. QuidelOrtho has a twelve month low of $9.92 and a twelve month high of $35.58. The company has a market capitalization of $938.24 million, a P/E ratio of -0.89 and a beta of 0.79. The firm has a 50 day moving average of $12.80 and a 200 day moving average of $16.87. The company has a quick ratio of 0.76, a current ratio of 1.39 and a debt-to-equity ratio of 1.43.

Analyst Upgrades and Downgrades

A number of analysts have commented on QDEL shares. Citigroup lifted their target price on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Zacks Research raised QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Friday, October 9th. JPMorgan Chase & Co. increased their price objective on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research report on Wednesday, July 1st. Jefferies Financial Group reiterated a “hold” rating on shares of QuidelOrtho in a report on Monday, June 29th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research report on Thursday, October 15th. Four investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $13.62.

About QuidelOrtho

QuidelOrtho Corporation (NASDAQ:QDEL) is a global in vitro diagnostics company formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, a transaction completed in 2022. The company develops, manufactures and markets diagnostic technologies used to detect disease, guide treatment decisions and support blood-transfusion safety.

Its portfolio includes rapid immunoassays, molecular testing systems, clinical chemistry and immunohematology products, as well as laboratory automation solutions.